Early side effects and first results of radioligand therapy with $^{177}$Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Hojjat Ahmadzadehfar$^{1*}$, Kambiz Rahbar$^{2†}$, Stefan Kürpig$^1$, Martin Bögemann$^3$, Michael Claesener$^2$, Elisabeth Eppard$^1$, Florian Gärtner$^1$, Sebastian Rogenhofer$^4$, Michael Schäfers$^{2,5}$ and Markus Essler$^1$

**Abstract**

**Background**: Radioligand therapy (RLT) with $^{177}$Lu-DKFZ-617 PSMA (Lu-PSMA) (prostate-specific membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We analysed retrospectively the early side effects and the response rate in the first patients, who received a therapy with Lu-PSMA in our departments.

**Methods**: RLT was performed in ten hormone- and/or chemo-refractory patients with distant metastases and progressive disease (mean age 73.5 years). $^{68}$Ga-PSMA HBED-CC PET/CT was performed in all patients prior to RLT. The median PSA level prior to the therapy was 298.5 ng/ml (range 5–853 ng/ml). All patients received CBC, renal and liver function tests the day before and 2 days after application (mean administered activity 5.6 GBq, range 4.1–6.1 GBq), followed by further tests every 2 weeks. All patients were contacted by telephone every week regarding side effects or any positive and negative changes.

**Results**: Eight weeks after the therapy, seven patients (70 %) experienced a PSA decline, of whom six experienced more than 30 % and five more than 50 %. Three patients showed a progressive disease according to the PSA increase. No patient experienced any side effects immediately after injection of Lu-PSMA. Relevant hematotoxicity (grade 3 or 4) occurred 7 weeks after the administration in just one patient. The same patient showed leucopenia grade 2. Two patients showed a disturbance of only 1 hematologic cell line, whereas one patient showed a reduction of grades 1 and 2 in leucocytes and thrombocytes, respectively. Six patients did not show any hematotoxicity during the 8 weeks after therapy. There was no relevant nephrotoxicity (grade 3 or 4).

**Conclusions**: Our initial results indicate that RLT with Lu-PSMA is safe and seems to have low early side-effect profile. A relevant PSA decline was detected in 70 % of patients.

**Keywords**: Prostate cancer; PSMA; Radioligand therapy; 177Lu

**Background**

Prostate cancer (PCa) is the second most common cancer worldwide in male and the fourth most common cancer overall [1]. In patients with localised PCa, the five-year survival rate approximates 100 %; however, in patients with distant metastases, the five-year survival rate drops to 31 % [2]. Almost all patients with metastatic PCa will initially respond to well-established and innovative anti-androgen treatments including the two recently approved hormone therapy agents, the androgen receptor antagonist enzalutamide and the CYP17A1-inhibitor abiraterone [3, 4] which significantly improve the overall survival. However, progression to androgen independence is the main cause of death in prostate cancer patients [5]. Most deaths related to PCa are due to advanced disease, which results from any combination of lymphatic, blood, or contiguous local spread. Targeted radionuclide
therapy is an attractive and quickly developing therapy option for many different cancers, such as lymphoma, melanoma, and neuroendocrine tumours [6–9]. Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. The PSMA expression levels are directly correlated to androgen independence, metastasis, and PCa progression [10]; therefore, PSMA is an attractive target for diagnosis and therapy of metastasised prostate cancer. After rather unsuccessful therapy with $^{90}$Y-CYT-356 monoclonal antibody (mAb) that binds to the intracellular domain of PSMA [11], phases 1 and 2 clinical trials utilising the PSMA mAb J591, radiolabelled with $^{90}$Y or $^{177}$Lu, have shown promising results [12–15]. Recently, a novel theranostic drug, $^{177}$Lu-DKFZ-617, which is a DOTA derivative of the Glu-urea-Lys motif, has been developed in the Department of Nuclear Medicine, University Hospital Heidelberg, Germany, for the treatment of patients with metastatic prostate cancer [16, 17]. In this study, we analysed retrospectively the early side effects and the response rate in the first patients, who received a therapy with $^{177}$Lu-DKFZ-617 PSMA (Lu-PSMA), in our departments as the last possible option [18].

**Methods**

Ten consecutive hormone- and/or chemo-refractory PCa patients with distant metastases and progressive disease according to the PSA level were treated with Lu-PSMA between November 2013 and January 2014 in two different centres (University Hospital Bonn and University Hospital Muenster). All patients underwent a $^{68}$Ga-PSMA HBED-CC ($^{68}$Ga-PSMA) PET/CT prior to therapy to evaluate the PSMA expression status of the metastases. The majority of patients had bone metastases as well as lymph node metastases. The extent of metastases in the patients is shown in Table 1. The written information regarding the therapy and its possible side effects was provided to each patient at two time points: first after the PET scan and once again 24 h prior to therapy. The local committee on ethics approved this retrospective study, and all subjects had provided prior written informed consent.

| Number | Age (y/o) | Metastases | History of CTx | Dose GBq |
|--------|-----------|------------|----------------|----------|
| 1      | 70        | Bone3, Ln1, LR | No            | 5.8      |
| 2      | 77        | Bone3, LR    | Yes            | 6.1      |
| 3      | 67        | Bone3, Ln1, LR | Yes          | 6.0      |
| 4      | 75        | Bone3, Ln1    | No            | 5.9      |
| 5      | 77        | Bone3, Ln2    | No            | 4.1      |
| 6      | 81        | Bone3, Ln1    | No            | 5.9      |
| 7      | 62        | Ln2          | Yes            | 5.8      |
| 8      | 74        | Ln2, liver met | Yes          | 5.7      |
| 9      | 76        | Bone1, Ln1    | Yes            | 5.8      |
| 10     | 76        | Bone3, Ln1    | No            | 5.2      |

Bone1 <6 bone metastases, bone2 6–20 bone metastases, bone3 >20 bone metastases
Ln1 lymph node metastasis (abdominal, iliacal and inguinal), ln2 Ln1 + thoracal lymph node metastasis, LR local recurrence, CTx chemotherapy

Muenster. Depending on the clinical situation and the availability of previous CT examinations, either a diagnostic CT including the application of intravenous contrast media or a low-dose CT without contrast agent was performed.

**Renal function test and renal scintigraphy with $^{99m}$Tc-MAG3**

Creatinine and glomerular function tests (GFR) were performed in all patients prior to the therapy and every 2 weeks afterwards. To rule out any renal obstructive disease as well as for the measurement of the tubular extraction rate of MAG3 (TER MAG3), all patients underwent a renal perfusion scintigraphy with $^{99m}$Tc-MAG3 within 1 week prior to and 8 weeks after the therapy. The scans were performed using dual-head SPECT cameras (AnyScan, Mediso at the University Hospital Bonn and Siemens E-Cam at the University Hospital Muenster). This procedure has been described in detail elsewhere [19, 20].

**Salivary gland scintigraphy with $^{99m}$Tc-Pertechnetate**

To evaluate the functional impairment of the salivary glands, all patients received a dynamic salivary gland scintigraphy with Tc-Pertechnetate combined with salivary gland stimulation by lemon juice 20 min p.i. on the treatment day as well as 8 weeks after the therapy. The scans were performed on a triple-head SPECT camera (Irix Philips) at the University Hospital Bonn and on a dual-head SPECT camera (Siemens E-Cam) at the University Hospital Muenster. The scintigraphic procedure has been described in detail elsewhere [21].

**Radioligand therapy (RLT)**

PSMA was obtained from ABX GmbH (Radeberg, Germany). To begin, 1 mg DOTA-PSMA was dissolved in...
1 ml 0.05 M HCl. Then, 88.50 ± 9.21 µg DOTA-PSMA per 10 µg Lu was added to 1 ml 0.05 M HCl solution containing 42 mg gentisinic acid and 210 mg sodium ascorbate. This mixture was added to carrier-added $^{177}$LuCl$_3$, obtained from IDB Holland, and heated for 30 min at 95 °C. Quality control was performed by spotting 1 µl aliquots on TLC (SilicaGel 60, Merck, Darmstadt, Germany) with 0.1 M citric buffer or ITLC-SG plates (ITLC-SG, Varian, Lake Forest, CA, USA) and with 1 M NH$_4$OAc/MeOH (1:1) as solvent. Analysis was performed using a flat-bed scanner (Rita Star, Raytest-Isotopenmessgeräte GmbH, Straubenhardt, Germany). Radiochemical purity was determined by radio HPLC, which was performed using a gradient system. The gradient elution system utilised mobile phase A (deionised H$_2$O containing 0.1 % TFA) and mobile phase B (100 % acetonitrile) and a flow rate of 1.0 ml/min. Starting with 100 % A/0 % B, the gradient was increased to 100 % B over 30 min and then returned to the initial gradient conditions within 5 min. The retention time of free $^{177}$Lu was $R_t = 2.5$ min, whereas for Lu-PSMA it was 13.3 min.

The labelling yield always exceeded 95 % (98.85 ± 1.29 %); therefore, no purification was performed. The radiochemical purity was higher than 98 %. The specific activity of Lu-PSMA was 89.73 ± 13.61 MBq/µg.

The therapy solution was administered by slow intravenous injection over 1 min followed by 1000 ml of NaCl or Ringer. In order to reduce therapy-induced damage to the salivary glands, the patients received ice packs over the parotid and submandibular glands from 30 min prior to and up to 4 h after administration of the Lu-PSMA. All patients were discharged 48 h after therapy according to the rules of the Federal Office for Radiation Protection in Germany (BfS).

**Data collection and follow-up**

One day prior to and 2 days after therapy, the haematological and renal status, liver function tests, tumour marker PSA, alkaline phosphatase, and blood biochemistry were evaluated in all patients. The ECOG performance-status score, the therapy-induced side effects during the time of hospitalisation and at follow-up, and laboratory examinations at two-week intervals for up to 8 weeks after therapy were obtained in all patients. All patients were contacted by telephone regularly in one- to two-week intervals. The blood examinations were conducted by the urologists and faxed to our departments.

**Tumour response evaluation**

The tumour marker PSA was used as the main marker for the response evaluation. We classified the changes of PSA level as decreasing more than 50 %, more than 30 %, and any decline. An increase of ≥25 % was evaluated as progress.

**Toxicity**

Toxicity was recorded with the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, and was analysed according to the recommendation of NCI guidelines for investigators.

**Results**

Ten hormone- and/or chemo-refractory patients with a mean age of 73.5 years (range 62–81) underwent $^{68}$Ga-PSMA PET/CT followed by therapy with a mean of 5.6 GBq Lu-PSMA (range 4.1–6.1 GBq). All patients had a history or were under therapy with enzalutamide and/or abiraterone. Four patients had received $^{223}$Ra-dichloride (1–4 cycles). Eight patients showed PSMA-positive bone and lymph node metastases, from whom seven had a massive metastatic disease with more than 20 bone metastases (Table 1). Three patients (patients 1–3; Table 1) also showed local recurrence. One patient had only lymph node metastases (patient 7; Table 1) and one had a liver metastasis along with lymph node metastases (patient 8; Table 1). The mean and median PSA levels prior to the therapy were 339.4 and 298.5 ng/ml, respectively (range 5–853 ng/ml).

Nine patients exhibited good Eastern Cooperative Oncology Group (ECOG) performance-status scores (0 or 1; Table 2). The blood parameters are shown in Table 3.

Two patients (patient 4 and 10) had received blood transfusion prior to therapy because of grade 3 anaemia, and patient 9 had received blood transfusion because of bleeding in the bladder, which consisted till 7 weeks after the therapy.

**Response evaluation 2 months after therapy**

Eight weeks after the therapy, seven patients (70 %) experienced a PSA decline, out of whom six experienced more than 30 % and five more than 50 %. Three patients showed a progressive disease according to the PSA increase (Table 2, Fig. 1).

**Complaints and side effects during hospitalisation**

No patient experienced any side effects immediately after injection of Lu-PSMA. No significant change in blood pressure or body temperature was observed. One patient complained of a light headache 1 day after application (patient 2). The pain was exactly in the region of his bone metastasis on the skull. It was treated successfully with one 400-mg dose of ibuprofen. The same patient had dry lips beginning 2 days after application and lasting for 2 weeks. One patient experienced mild nausea (patient 10), and one (patient 4) with a history of intermittent nausea experienced nausea and one instance of...
vomiting about 6 h after administration of the Lu-PSMA. In both patients, the nausea was controlled easily with ondansetron. Otherwise, the patients tolerated the therapy very well.

Complaints and side effects between the second day and 2 months after therapy

Two patients complained of fatigue and two other patients complained of hypogeusia and dry lips in the first 2 weeks (Table 4). Patient 4 experienced fatigue 7 weeks after the therapy due to anaemia (Hb 6.9), which was treated with 2 units of packed red blood cells (pRBC). No patient experienced a negative change in performance status (Tables 2 and 4).

The follow-up salivary gland scintigraphy 2 months after therapy showed no significant change in the uptake and clearance of $^{99m}$Tc from the salivary glands.

Hematotoxicity

The mean Hb, WBC, and Plt prior to therapy were 11.0, 6.6, and 234.9 g/l, respectively (Table 3).

Relevant hematotoxicity (grade 3 or 4) occurred 7 weeks after the administration in just one patient, who had a history of blood transfusion prior to therapy (patient 4). The same patient showed a leucopenia grade 2. Two patients showed a disturbance of only 1 hematologic cell line (thrombocytopenia, 1; anaemia, 1), whereas one patient showed a reduction of grades 1 and 2 in leucocytes and thrombocytes, respectively. Six patients (60 %) did not show any hematotoxicity during the 8 weeks after therapy (Table 3).

Nephrotoxicity

There was no relevant nephrotoxicity (grade 3 or 4). One patient showed a grade 1 and one with a known renal insufficiency showed a grade 2 toxicity (Table 5).

| Table 2 | Performance status and baseline PSA level as well as PSA changes 8 weeks after therapy |
|---------|-------------------------------------------------------------------------------------|
| Number  | ECOG1 | ECOG2 | Baseline PSA (ng/ml) | PSA2 (ng/ml) | PSA change (%) |
|---------|-------|-------|----------------------|--------------|---------------|
| 1       | 1     | 1     | 226                  | 529          | 134.7         |
| 2       | 1     | 1     | 334                  | 243          | −27.2         |
| 3       | 2     | 2     | 376                  | 141          | −62.5         |
| 4       | 1     | 1     | 853                  | 590          | −30.8         |
| 5       | 1     | 1     | 148                  | 46           | −68.9         |
| 6       | 0     | 0     | 20                   | 5            | −75.0         |
| 7       | 1     | 1     | 263                  | 355          | 35.0          |
| 8       | 1     | 1     | 790                  | 293          | −62.9         |
| 9       | 1     | 1     | 379                  | 58           | −84.7         |
| 10      | 3     | 2     | 21                   | 21           | 320.0         |

ECOG1 baseline Eastern Cooperative Oncology Group performance status, ECOG2 Eastern Cooperative Oncology Group performance status 2 months after therapy, PSA prostatic specific antigen, PSA2 prostatic specific antigen 2 months after therapy

*a 4 weeks after Tx, PSA decreased to 71 ng/ml

| Table 3 | Hb, WBC and Plt values on the treatment day and hematotoxicity measured 2 months after Lu-PSMA therapy |
|---------|-----------------------------------------------------------------------------------------------------|
| Number  | Baseline Hb (g/dl) | CTC Hb | Baseline WBC (g/l) | CTC WBC | Baseline Plt (g/l) | CTC Plt |
|---------|-------------------|-------|-------------------|--------|-------------------|--------|
| 1       | 9.6               | 0     | 7.4               | 0      | 352               | 0      |
| 2       | 11                | 0     | 7.1               | 0      | 322               | 0      |
| 3       | 9.0               | 0     | 4.7               | 0      | 181               | 1      |
| 4       | 11.7              | 3     | 3.3               | 2      | 62                | 0      |
| 5       | 11.5              | 0     | 5.9               | 0      | 170               | 0      |
| 6       | 14.5              | 0     | 8.8               | 0      | 234               | 0      |
| 7       | 11.4              | 0     | 8.0               | 0      | 295               | 0      |
| 8       | 12.2              | 1     | 10.1              | 0      | 313               | 0      |
| 9       | 9.3               | 0     | 3.4               | 1      | 99                | 2      |
| 10      | 9.9               | 0     | 7.3               | 0      | 321               | 0      |

Patient 4, 9 and 10 had received blood transfusion prior to therapy because of low Hb levels

CTC common toxicity criteria 2 months after therapy, Hb hemoglobin, Plt platelet, WBC white blood cells
Hepatic toxicity

There was no toxicity except for one grade 1 hypoalbuminemia (Table 6).

Discussion

Targeted radionuclide therapy is a state of the art and rapidly developing therapy option for different cancer types. The potential advantage of targeted radionuclide therapy is saving the normal tissue while giving a high radiation dose to the tumour. PSMA is highly overexpressed by almost all prostate cancer cells; hence, it is an optimal target for radionuclide therapy. Tagawa et al. presented the results of a phase II study of radionuclide therapy with Lu-PSMA mAb J591 [12], which was based on two former phase 1-published studies with this agent [13, 22]. mAb are large molecules and therefore show a poor permeability in solid tumours and slow clearance from the circulation. This combination leads to suboptimal tumour targeting and an increased absorbed dose to red marrow, narrowing the therapeutic window [23]. Maresca et al. described the design and synthesis of a series of small molecule inhibitors of PSMA [24]. On the basis of this work, Hiller et al. [17] did the preclinical evaluation of two radiopharmaceuticals, $^{123}$I-MIP-1072 and $^{123}$I-MIP-1095, that were designed to target PSMA in prostate cancer cells and tissue. In a very recent published study from the Heidelberg group, Zechmann et al. showed the utility of $^{131}$I-MIP-1095 PSMA [23]. In contrast to mAb, the low molecular weight compounds, with higher permeability into solid tumours, offer a significant advantage in achieving higher uptake per gramme of tumour tissue and a high percentage of specific binding. Furthermore, small molecules display more rapid tissue distribution and faster blood clearance compared with intact immunoglobulins. These properties often lead to an enhanced target to non-target tissue ratio, which is important not just for imaging but also for successful application of therapeutic absorbed doses [23]. $^{131}$I has a half-life of 8.02 days with a high environmental radiation burden according to the high gamma energy, which limits its utility because of complex radiation protection regulations in most countries. In contrast to $^{131}$I, $^{177}$Lu causes a lower local dosis rate, and therefore a lower radiation burden for staff and contact persons. Furthermore, the higher specific activity of $^{177}$Lu compared to commercially available $^{131}$I makes $^{177}$Lu preferable for targeted radionuclide therapies. Late renal toxicity of $^{177}$Lu-PSMA is subject of further studies.

In this paper, we introduced the first experiences with Lu-PSMA in our departments for the treatment of metastatic prostate cancer. Our patients did not have any other therapy option and were selected very carefully for

### Table 4 Side effects and complaints in the first 2 days, 4 weeks and between 4 and 8 weeks

| Number | In the first 2 days | During the first 4 weeks | 4–8 weeks |
|--------|--------------------|--------------------------|-----------|
| 1      | No                 | No                       | No        |
| 2      | Dry lips           | Dry lips just in the first 2 weeks | No |
|        | Light headache     |                          |           |
| 3      | No                 | No                       | No        |
| 4      | Nausea and vomiting just 1 time | No | Fatigue in the 7th week because of anaemia, patient received red blood cell transfusion |
| 5      | No                 | Hypogeusia in the first 2 weeks | No        |
| 6      | No                 | No                       | No        |
| 7      | No                 | No                       | No        |
| 8      | No                 | No                       | Fatigue   |
| 9      | No                 | No                       | No        |
| 10     | Nausea             | No                       | No        |
this therapy in cooperation with their urologists or oncolgists. The first and the most important issue for us was the tolerability of the therapy regarding incidence of post therapy symptoms as well as toxicities. Our second aim was to evaluate the therapy response after a single dose application of this agent.

The tolerability was very good, and no patient experienced any serious side effects in the time of hospitalisation or afterwards.

Tagawa et al. [12] treated 47 patients with Lu-PSMA mAb J591. In their study, a total of 10.6 % experienced >50 % decline in PSA, 36.2 % experienced >30 % decline, and 59.6 % experienced any PSA decline following their single treatment. All patients experienced reversible hematologic toxicity, with grade 4 thrombocytopenia occurring in 46.8 % (29.8 % received platelet transfusions) without significant haemorrhage. A total of 25.5 % experienced grade 4 neutropenia. Zechmann et al. [23] reported a decline in serum PSA levels of ≥50 % in 60.7 % of patients and a drop between 0 and 50 % after a single dose of $^{131}$I-MIP-1095 PSMA in 14.2 % of patients. In our study 70 % of the patients showed a decline in PSA level, with 50 % of them at more than 50 %. Here, we have to mention that we introduce the preliminary results of our therapies in this paper, and comparison of the results of our study with these two studies is not justified for many reasons, including the different types of the studies (prospective vs. retrospective), the number of patients, and the duration of follow-up.

In most cases there was extensive skeletal and lymph node involvement, and a majority of patients were clinically anaemic at the time of treatment; however, a mild hemototoxicity was observed in just three patients. In the time of Lu-PSMA therapy, the Hb value of patient 4, who had a history of four cycles of $^{223}$Ra therapy, was 11.7 g/dl, and therefore, we classified his Hb decline 7 weeks after therapy as grade 3 toxicity. This patient also suffered from a chronic thrombocytopenia after four cycles of therapy with $^{223}$Ra, and the decision for the Lu-PSMA therapy was made after a detailed clarification of all possible side effects. The number of thrombocytes did not change in the follow-up time.

Because of the physiological PSMA expression in the kidneys, there is concern regarding potential toxicity due to radiation to the kidneys. Zechmann et al. [23] reported after therapy with $^{131}$I-MIP-1095 PSMA that there was no apparent evidence or negative trend in either calculated GFR or serum creatinine levels in a one-year follow-up. In our study, no patient experienced a grade 3 nephrotoxicity, and one patient with known renal insufficiency showed a grade 2 nephrotoxicity and one patient a grade 1. Apart from blood GFR and creatinine, renal scintigraphy with Tc-MAG3 is a valuable examination prior to therapy to rule out any relevant obstructive disease. An obstructive disease should be treated in advance for reducing the delivered dose to the affected kidney. We have to mention here that after a two-month follow-up, we can rule out acute renal insufficiencies, but we have to do a longer follow-up to determine any chronic side effects.

| Table 5 Nephrotoxicity |
|------------------------|
| **Number** | **Cr** | **CTC Cr** | **GFR (ml/min)** | **CTC GFR** | **Baseline TER MAG3** | **Second TER MAG3** |
|------------------------|
| 1 | 1.0 | 1 | >70 | 1 | 183 | 179 |
| 2 | 1.3 | 0 | 56 | 0 | 125 | 104 |
| 3 | 0.8 | 0 | >70 | 0 | 245 | 209 |
| 4 | 0.6 | 0 | >70 | 0 | 186 | 178 |
| 5 | 1.5 | 2 | 50 | 2 | 92 | 96 |
| 6 | 0.7 | 0 | >70 | 0 | 208 | 220 |
| 7 | 0.6 | 0 | >70 | 0 | 270 | 284 |
| 8 | 1.2 | 0 | >70 | 0 | 156 | 220 |
| 9 | 0.8 | 0 | >70 | 0 | 214 | 214 |
| 10 | 0.9 | 0 | >70 | 0 | 231 | 256 |

Cr creatinine, GFR glomerular filtration rate, TER MAG3 tubular extraction rate of MAG3 (ml/min/1.73 m$^2$ BSA)

| Table 6 Liver toxicity |
|-----------------------|
| **Number** | **CTC ALT** | **CTC AST** | **CTC albumin** |
|-----------------------|
| 1 | 0 | 0 | 0 |
| 2 | 0 | 0 | 0 |
| 3 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 |
| 5 | 0 | 0 | 1 |
| 6 | 0 | 0 | 0 |
| 7 | 0 | 0 | 0 |
| 8 | 0 | 0 | 0 |
| 9 | 0 | 0 | 0 |
| 10 | 0 | 0 | 0 |

ALT alanine aminotransferase, AST aspartate aminotransferase, CTC common toxicity criteria
Regarding xerostomia, because of the physiologic uptake of this tracer in salivary glands, the side effects were mild and transient and occurred in just two patients. We do not know for certain whether a cooling of the salivary glands is an effective therapy for saving these glands from radiation; however, using it is tolerable for the patients and is not harmful. There is a need to plan a PET study regarding this issue measuring the change in uptake of \(^{68}\)Ga-PSMA with and without ice packs.

As mentioned before, this paper presents our first experiences with Lu-PSMA, and we are going to increase our knowledge about this therapy. There are some important issues which should be studied in the future, such as the number of cycles, the maximal tolerable dose, and the quality of life of these patients. One of the most important questions is whether there is a positive effect on overall survival, which needs a long follow-up time.

**Conclusions**

Our initial results indicate that a single dose of Lu-PSMA for the treatment of metastatic prostate cancer patients without any other therapy option is safe and seems to have a low early side-effect profile with evidence of positive response to the therapy according to PSA decline in 70 % of patients.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

HA and KR wrote the paper together. HA, KR, ME and MS participated in the design of the study. HA and MS participated in the coordination of the study. HA and SK performed the statistical analysis. HA, KR, SR and MB collected the data and made the SPSS table. FG, EE and MC contributed to the concept of the study and critical revision of the article as well as comparing the data mentioned in the manuscript with the data on SPSS table. All authors read and approved the final manuscript.

**Acknowledgements**

We are grateful to Professor Dr. Uwe Haberkorn and Dr. Clemens Kratochwil for sharing their experiences in the RLT with Lu-PSMA and for making this treatment possible at our institutions. We also are grateful to the nursing staff of the therapy wards of our departments. Finally, we give special thanks to our study nurse, Mrs. Ulrike Kuhn-Seifer (Department of Nuclear Medicine Bonn).

**Author details**

1. Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany.
2. Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.
3. Department of Urology, University Hospital Muenster, Muenster, Germany.
4. European Institute for Molecular Imaging, University of Muenster, Muenster, Germany.

**Received:** 27 April 2015 **Accepted:** 5 June 2015 **Published online:** 20 June 2015

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi:10.1002/ijc.29210.

2. Jamal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–302. doi:10.3322/caac.20073.

3. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. doi:10.1056/NEJMoa1207506.

4. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(12):1526–60. doi:10.1016/S1470-2045(15)71005-7.

5. Wei Q, Li M, Fu X, Tang R, Na Y, Jiang M, et al. Global analysis of differentially expressed genes in androgen-independent prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(2):167–74. doi:10.1038/jpcr.2007.93.

6. Kraeber-Bodere F, Bodec-Milin C, Rousseau C, Eugene T, Pailardy A, Frampas E, et al. Radioimmunoconjugates for the treatment of cancer. Semin Oncol. 2014;41(5):613–22. doi:10.1053/j.seminoncol.2014.07.004.

7. Mier W, Kratochwil C, Hassel JC, Giesel FL, Beijer B, Babich JW, et al. Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. J Nucl Med. 2014;55(1):9–14. doi:10.2967/jnumed.113.112789.

8. van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kools LK, Kwekkeboom DJ. GEPNETs update: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol. 2015;172(1):R1–8. doi:10.1530/EJE-14-0488.

9. Bodei L, Kidd M, Paganelli G, Grana CM, Drostov I, Cremonesi M, et al. Long-term tolerability of PARP in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(5):15–19. doi:10.1007/s00259-014-2893-5.

10. Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cisini S, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014;28(4):555–63.

11. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res. 1996;2(8):1289–97.

12. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Chritos P, Akhtar NH, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody JS91 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2015;19(18):4891–9. doi:10.1158/1078-0432.CCR-13-0231.

13. Bander NH, Milowski MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23(21):4591–601. doi:10.1200/JCO.2005.05.1660.

14. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled JS91 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46(3):850–8.

15. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowski MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled JS91 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11(19 Pt 2):7195s–2005s. doi:10.1158/1078-0432.CCR-05-0023.

16. Kratochwil C, Giesel FL, Eder M, Afhar-Oromieh A, Benesova M, Mier W et al. [Lu]luteum-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/00259-014-2979-1.

17. Hillier SM, Maresca KP, Fermia FJ, Marquis JC, Foss CA, Nguyen N, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69(17):6932–7. doi:10.1158/0008-5472.CAN-09-1682.

18. National Cancer Institute Guidelines For Investigators. Adverse event reporting requirements for DTCI DCTD (CTEP and CIP) and DCP INDs and IDEs. 2013.

19. Zajic T, Moser E. Procedure guidelines for dynamic renal scintigraphy. Nuklearmedizin. 2004;43(1):177–80. doi:10.1207/SNKL0405177.

20. Bubeck B, Brandau W, Weber E, Pomer S, Georgi P, zum Winkel K. Renal function studies using 99mTc-MAG3: pharmacokinetics and slope clearance determination. Contrib Nephrol. 1990;79:7–2–3.
21. MacDonald A, Burrell S. Infrequently performed studies in nuclear medicine: part 2. J Nucl Med Technol. 2009;37(1):1–13. doi:10.2967/jnmt.108.057851.

22. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody JS91 for androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2522–31. doi:10.1200/JCO.2004.09.154.

23. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs B, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41(7):1280–92. doi:10.1007/s00259-014-2713-y.

24. Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal J, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52(2):347–57. doi:10.1021/jm800994j.